Acalabrutinib Monotherapy for CLL: What It Can and Cannot Do

　　Acalabrutinib used on its own can bring meaningful disease control to some people with chronic lymphocytic leukemia(CLL),but it does not guarantee a definitive cure.The aim of treatment is to slow disease progression,relieve symptoms,and maintain remission,and the actual outcome depends on disease features and individual patient factors.

　　1.What acalabrutinib monotherapy does

　　Acalabrutinib inhibits BTK signaling,disrupting the survival and proliferation of CLL cells.In patients who meet treatment criteria,monotherapy can help control rising lymphocyte counts and enlarged lymph nodes while delaying disease progression.Response should be assessed by combining blood tests,physical examination,and disease-related symptoms.

　　2.Is remission the same as being cured?

　　No.CLL is typically a slow-growing blood cancer.Targeted therapy may produce a partial or even complete remission,but remission does not mean every leukemic cell has been eliminated.Even when test results improve substantially,ongoing monitoring remains essential to detect any signs of the disease becoming active again.

　　3.Why treatment often continues long term

　　Acalabrutinib monotherapy is generally continued until disease progression or unacceptable toxicity occurs.Sustained BTK suppression helps maintain disease control,which is why many patients stay on the drug for a long time.If the disease progresses,tolerability declines,or significant adverse effects develop,the treatment team will reassess the plan.Length of time on the drug alone is not a measure of treatment success.

　　4.Options when monotherapy is not enough

　　Other approaches for CLL include alternative BTK inhibitors,the BCL-2 inhibitor venetoclax,and,in certain situations,regimens combining anti-CD20 monoclonal antibodies.The choice depends on prior treatment history,genetic and chromosomal test results,coexisting conditions,and the risk of adverse reactions.